UK markets close in 1 minute

C4 Therapeutics, Inc. (CCCC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.77-0.20 (-3.35%)
As of 11:27AM EDT. Market open.
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-126,074
-132,493
-128,175
-83,892
-66,335
Depreciation & amortisation
1,783
1,880
1,676
1,492
1,617
Stock-based compensation
27,199
27,235
30,016
21,512
3,432
Change in working capital
2,639
-6,938
-16,779
-30,090
-13,177
Accounts receivable
-13,071
-10,327
4,244
-1,232
139
Accounts payable
593
273
-3,333
-1,179
467
Other working capital
-92,950
-108,546
-111,435
-88,242
-67,899
Other non-cash items
6,404
6,641
6,609
2,134
1,633
Net cash provided by operating activities
-91,831
-106,838
-105,939
-86,965
-67,249
Cash flows from investing activities
Investments in property, plant and equipment
-
-1,708
-5,496
-1,277
-650
Purchases of investments
-226,209
-129,898
-219,527
-537,740
-293,855
Sales/maturities of investments
278,750
289,955
283,445
349,681
104,000
Net cash used for investing activities
51,422
158,349
58,422
-189,336
-190,505
Cash flows from financing activities
Debt repayment
-11,750
-12,500
0
-
-
Common stock issued
91,762
57,673
0
169,465
340,599
Common stock repurchased
-125
-110
0
0
-194
Other financing activities
348
368
370
-395
-3,606
Net cash used provided by (used for) financing activities
80,756
45,489
1,147
171,400
348,932
Net change in cash
40,347
97,000
-46,370
-104,901
91,178
Cash at beginning of period
52,755
33,033
79,403
184,304
93,126
Cash at end of period
93,102
130,033
33,033
79,403
184,304
Free cash flow
Operating cash flow
-91,831
-106,838
-105,939
-86,965
-67,249
Capital expenditure
-
-1,708
-5,496
-1,277
-650
Free cash flow
-92,950
-108,546
-111,435
-88,242
-67,899